New research reveals that patients who stop using popular GLP-1 drugs like semaglutide or tirzepatide may regain lost weight far faster than those who stop traditional diet and exercise regimens.
Research printed in a leading health publication shows that while overweight people often shed substantial amounts of their total mass while on the medication, the weight returns at an average rate of 0.8 kg per month after stopping.
"Individuals purchasing these medications must be aware of the potential of quick weight regain when the medication concludes," cautioned lead investigator Dr. Susan Jebb.
This pace of recovery suggests a return to starting mass within about 18 months.
Weighing Approaches
The study, which examined 37 of trials involving over 9,000 of participants, contrasted the effects of the injectable medications with conventional dieting.
Researchers emphasize that people who lose weight through dieting generally have a less rapid weight regain—perhaps 100 grams monthly—once they finish.
Understanding the Quick Regain
Doctors propose the mode of action of the drugs explains the accelerated rebound.
GLP-1 drugs mimic a body's own chemical called glucagon-like peptide-1, which helps regulate feelings of fullness.
"Sustained high doses of the hormone concentrations far above than the body's typical production might result in the body to generate a reduced amount of its own natural hormone, and may also lessen responsiveness to its effects," said Dr. Adam Collins, a nutrition researcher.
"Discontinuation of this GLP-1 'fix' means appetite is no longer kept in check, making excessive eating much more probable."
A Lifelong Condition?
The NHS suggest the injections for individuals with obesity-related medical conditions, alongside prescribed lifestyle changes.
A number of clinicians argue that, given the likelihood of relapse, the treatment should be considered ongoing.
This perspective is echoed by drug manufacturers, who say that the results "highlight the long-term character of obesity," comparing it to managing conditions like hypertension.
Patient Testimonies
Users who have discontinued the medication describe a intense resurgence of hunger.
"It was like something activating and you become ravenous," described a patient.
This difficulty is worsened if users have not established permanent dietary or behavioural modifications during treatment.
Growing Adoption
Survey data show that a significant number of people in the UK have tried these injections in the last 12 months, with interest remaining high.
- Adoption is more common among women than men.
- The 40s and 50s demographic shows the greatest level of interest.
- Many access the medications through private healthcare rather than public health services.
Ultimately, clinicians stress that while these medications are potent tools for shedding pounds, they are not a magic solution and long-term success hinges on ongoing lifestyle support.
